Hipofosfatemia inducida por drogas: fierro carboximaltosa e imatinib. Casos clínicos

Hypophosphatemia is a relatively frequent and a potentially serious adverse drug effect. Clinically it is characterized by bone pain and muscle weakness. There are several mechanisms by which a drug can induce hypophosphatemia and they can be classified according to whether or not they are mediated...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ivanovic-Zuvic,Danisa, Fischman,Alexandra, Jiménez,Macarena, Martínez,Alejandra, Ernst,Daniel, Toro,Luis, Guarda,Francisco J., Florenzano,Pablo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2020
Materias:	Drug-Related Side Effects and Adverse Reactions Fibroblast Growth Factors Iron Compounds Hypophosphatemia Imatinib Mesylate
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000300404
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872020000300404
record_format	dspace
spelling	oai:scielo:S0034-988720200003004042020-06-11Hipofosfatemia inducida por drogas: fierro carboximaltosa e imatinib. Casos clínicosIvanovic-Zuvic,DanisaFischman,AlexandraJiménez,MacarenaMartínez,AlejandraErnst,DanielToro,LuisGuarda,Francisco J.Florenzano,Pablo Drug-Related Side Effects and Adverse Reactions Fibroblast Growth Factors Iron Compounds Hypophosphatemia Imatinib Mesylate Hypophosphatemia is a relatively frequent and a potentially serious adverse drug effect. Clinically it is characterized by bone pain and muscle weakness. There are several mechanisms by which a drug can induce hypophosphatemia and they can be classified according to whether or not they are mediated by an excess of Fibroblast Growth Factor 23 (FGF23). We report two patients with the condition: (i) A 49-year-old woman with Chronic Myeloid Leukemia (CML) and gastric sleeve surgery at 46 years of age. After receiving intravenous carboxymaltose iron in one occasion due to refractory anemia, she developed symptomatic hypophosphatemia. Urinary phosphate losses associated with high FGF23 levels were confirmed. Plasma phosphate returned to normal values 90 days after the iron administration. (ii) A 40-year-old man with a history of CML in whom imatinib was started. He developed symptomatic hypophosphatemia due to non FGF23-mediated hyperphosphaturia. As treatment with imatinib could not be interrupted, hypophosphatemia and its symptoms resolved with oral phosphate intake. These cases illustrate the importance of recognizing and treating drug-induced hypophosphatemia in a timely manner, and thus avoid the morbidity associated with this entity.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.148 n.3 20202020-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000300404es10.4067/S0034-98872020000300404
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Drug-Related Side Effects and Adverse Reactions Fibroblast Growth Factors Iron Compounds Hypophosphatemia Imatinib Mesylate
spellingShingle	Drug-Related Side Effects and Adverse Reactions Fibroblast Growth Factors Iron Compounds Hypophosphatemia Imatinib Mesylate Ivanovic-Zuvic,Danisa Fischman,Alexandra Jiménez,Macarena Martínez,Alejandra Ernst,Daniel Toro,Luis Guarda,Francisco J. Florenzano,Pablo Hipofosfatemia inducida por drogas: fierro carboximaltosa e imatinib. Casos clínicos
description	Hypophosphatemia is a relatively frequent and a potentially serious adverse drug effect. Clinically it is characterized by bone pain and muscle weakness. There are several mechanisms by which a drug can induce hypophosphatemia and they can be classified according to whether or not they are mediated by an excess of Fibroblast Growth Factor 23 (FGF23). We report two patients with the condition: (i) A 49-year-old woman with Chronic Myeloid Leukemia (CML) and gastric sleeve surgery at 46 years of age. After receiving intravenous carboxymaltose iron in one occasion due to refractory anemia, she developed symptomatic hypophosphatemia. Urinary phosphate losses associated with high FGF23 levels were confirmed. Plasma phosphate returned to normal values 90 days after the iron administration. (ii) A 40-year-old man with a history of CML in whom imatinib was started. He developed symptomatic hypophosphatemia due to non FGF23-mediated hyperphosphaturia. As treatment with imatinib could not be interrupted, hypophosphatemia and its symptoms resolved with oral phosphate intake. These cases illustrate the importance of recognizing and treating drug-induced hypophosphatemia in a timely manner, and thus avoid the morbidity associated with this entity.
author	Ivanovic-Zuvic,Danisa Fischman,Alexandra Jiménez,Macarena Martínez,Alejandra Ernst,Daniel Toro,Luis Guarda,Francisco J. Florenzano,Pablo
author_facet	Ivanovic-Zuvic,Danisa Fischman,Alexandra Jiménez,Macarena Martínez,Alejandra Ernst,Daniel Toro,Luis Guarda,Francisco J. Florenzano,Pablo
author_sort	Ivanovic-Zuvic,Danisa
title	Hipofosfatemia inducida por drogas: fierro carboximaltosa e imatinib. Casos clínicos
title_short	Hipofosfatemia inducida por drogas: fierro carboximaltosa e imatinib. Casos clínicos
title_full	Hipofosfatemia inducida por drogas: fierro carboximaltosa e imatinib. Casos clínicos
title_fullStr	Hipofosfatemia inducida por drogas: fierro carboximaltosa e imatinib. Casos clínicos
title_full_unstemmed	Hipofosfatemia inducida por drogas: fierro carboximaltosa e imatinib. Casos clínicos
title_sort	hipofosfatemia inducida por drogas: fierro carboximaltosa e imatinib. casos clínicos
publisher	Sociedad Médica de Santiago
publishDate	2020
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000300404
work_keys_str_mv	AT ivanoviczuvicdanisa hipofosfatemiainducidapordrogasfierrocarboximaltosaeimatinibcasosclinicos AT fischmanalexandra hipofosfatemiainducidapordrogasfierrocarboximaltosaeimatinibcasosclinicos AT jimenezmacarena hipofosfatemiainducidapordrogasfierrocarboximaltosaeimatinibcasosclinicos AT martinezalejandra hipofosfatemiainducidapordrogasfierrocarboximaltosaeimatinibcasosclinicos AT ernstdaniel hipofosfatemiainducidapordrogasfierrocarboximaltosaeimatinibcasosclinicos AT toroluis hipofosfatemiainducidapordrogasfierrocarboximaltosaeimatinibcasosclinicos AT guardafranciscoj hipofosfatemiainducidapordrogasfierrocarboximaltosaeimatinibcasosclinicos AT florenzanopablo hipofosfatemiainducidapordrogasfierrocarboximaltosaeimatinibcasosclinicos
_version_	1718437116978921472

Hipofosfatemia inducida por drogas: fierro carboximaltosa e imatinib. Casos clínicos

Ejemplares similares